<!DOCTYPE html><html lang="en"> <head> <meta charset="UTF-8"> <meta name="viewport" content="width=device-width, initial-scale=1.0"> <title>Module 1: Foundations of Emergency Pharmacology</title> <style> /* Main Styles from Previous Document */ body { font-family: 'Calibri', 'Segoe UI', sans-serif; line-height: 1.5; color: #2c3e50; margin: 2cm; background-color: #ffffff; counter-reset: chapter section figure table; }
    h1 {
        font-size: 28pt;
        font-weight: bold;
        color: #1a5276;
        text-align: center;
        border-bottom: 3px double #3498db;
        padding-bottom: 10px;
        margin-bottom: 30px;
    }
    
    h2 {
        font-size: 18pt;
        font-weight: bold;
        color: #ffffff;
        background-color: #2980b9;
        padding: 10px 15px;
        border-radius: 5px;
        margin-top: 30px;
        page-break-after: avoid;
    }
    
    h3 {
        font-size: 14pt;
        font-weight: bold;
        color: #154360;
        margin-top: 20px;
        margin-bottom: 10px;
        page-break-after: avoid;
    }
    
    h4 {
        font-size: 12.5pt;
        font-weight: bold;
        color: #21618c;
        margin-top: 15px;
        margin-bottom: 8px;
    }
    
    .module-title {
        font-size: 20pt;
        font-weight: bold;
        color: #21618c;
        margin-top: 40px;
        border-left: 6px solid #3498db;
        padding-left: 15px;
    }
    
    .chapter-number {
        background-color: #3498db;
        color: white;
        padding: 5px 12px;
        border-radius: 50%;
        display: inline-block;
        margin-right: 10px;
        font-weight: bold;
    }
    
    /* Lists */
    ul, ol {
        padding-left: 1.5em;
        margin-bottom: 1em;
    }
    
    li {
        margin-bottom: 8px;
        font-size: 11.5pt;
    }
    
    .sub-list {
        list-style-type: lower-alpha;
        padding-left: 2.5em;
    }
    
    .drug-list {
        columns: 2;
        column-gap: 50px;
        margin-top: 15px;
    }
    
    .drug-list li {
        break-inside: avoid;
    }
    
    /* Special Boxes */
    .study-format {
        background-color: #e8f4fc;
        border: 1px solid #aed6f1;
        border-left: 6px solid #2e86c1;
        padding: 20px;
        margin-top: 30px;
        page-break-inside: avoid;
    }
    
    .clinical-pearl {
        background-color: #fff3cd;
        border: 1px solid #ffeaa7;
        border-left: 6px solid #fdcb6e;
        padding: 15px;
        margin: 15px 0;
        border-radius: 0 5px 5px 0;
    }
    
    .warning-box {
        background-color: #f8d7da;
        border: 1px solid #f5c6cb;
        border-left: 6px solid #e74c3c;
        padding: 15px;
        margin: 15px 0;
        border-radius: 0 5px 5px 0;
    }
    
    .definition-box {
        background-color: #d1ecf1;
        border: 1px solid #bee5eb;
        border-left: 6px solid #17a2b8;
        padding: 15px;
        margin: 15px 0;
        border-radius: 0 5px 5px 0;
    }
    
    /* Tables */
    .comparison-table {
        width: 100%;
        border-collapse: collapse;
        margin: 20px 0;
        font-size: 11pt;
    }
    
    .comparison-table th {
        background-color: #2980b9;
        color: white;
        padding: 10px;
        text-align: left;
        border: 1px solid #1a5276;
    }
    
    .comparison-table td {
        padding: 10px;
        border: 1px solid #ddd;
        vertical-align: top;
    }
    
    .comparison-table tr:nth-child(even) {
        background-color: #f8f9fa;
    }
    
    /* Figures and Captions */
    .figure {
        text-align: center;
        margin: 20px 0;
        page-break-inside: avoid;
    }
    
    .figure img {
        max-width: 100%;
        height: auto;
    }
    
    .caption {
        font-style: italic;
        font-size: 10.5pt;
        color: #666;
        margin-top: 5px;
        text-align: center;
    }
    
    /* Page Layout */
    .page-break {
        page-break-before: always;
    }
    
    .footer-note {
        font-size: 9pt;
        color: #7f8c8d;
        text-align: center;
        margin-top: 30px;
        border-top: 1px solid #ecf0f1;
        padding-top: 10px;
    }
    
    /* Drug Template */
    .drug-template {
        background-color: #f9f9f9;
        border: 1px solid #ddd;
        padding: 20px;
        margin: 25px 0;
        border-radius: 5px;
        page-break-inside: avoid;
    }
    
    .drug-template h4 {
        color: #2c3e50;
        border-bottom: 2px solid #3498db;
        padding-bottom: 5px;
        margin-top: 0;
    }
    
    .template-section {
        margin-bottom: 15px;
    }
    
    .template-label {
        font-weight: bold;
        color: #2980b9;
        display: inline-block;
        width: 180px;
    }
    
    /* Emoji Styling */
    .emoji {
        font-size: 1.2em;
    }
    
    /* Print Specific */
    @media print {
        body {
            margin: 1.5cm;
            font-size: 11pt;
        }
        
        .page-break {
            page-break-before: always;
        }
        
        .no-print {
            display: none;
        }
        
        a {
            color: black;
            text-decoration: none;
        }
    }
    
    /* Learning Objectives */
    .learning-objectives {
        background-color: #e8f6f3;
        border: 1px solid #a2d9ce;
        padding: 15px;
        margin: 20px 0;
        border-radius: 5px;
    }
    
    .objective-list {
        list-style-type: none;
        padding-left: 0;
    }
    
    .objective-list li:before {
        content: "‚úì ";
        color: #27ae60;
        font-weight: bold;
        margin-right: 10px;
    }
</style>
</head> <body>
<div class="module-title">
    <span class="emoji">üü¶</span> MODULE 1: FOUNDATIONS OF EMERGENCY PHARMACOLOGY
    <div style="font-size: 12pt; font-weight: normal; font-style: italic; color: #7f8c8d;">
        (Must understand before drugs)
    </div>
</div>

<div class="learning-objectives">
    <h3 style="color: #148f77; margin-top: 0;">üìñ Learning Objectives</h3>
    <ul class="objective-list">
        <li>Define emergency medicine and understand its core principles</li>
        <li>Differentiate between key pharmacological terms (indication vs contraindication, side effects vs adverse effects)</li>
        <li>Master the five primary routes of injectable administration</li>
        <li>Understand drug preparation basics including dilution, concentration, and compatibility</li>
        <li>Recognize high-alert medications and LASA (Look-Alike/Sound-Alike) drugs</li>
        <li>Apply pediatric and adult dosing principles</li>
        <li>Perform basic renal and hepatic dose adjustments</li>
        <li>Manage anaphylaxis and drug reactions effectively</li>
    </ul>
</div>

<!-- CHAPTER 1 -->
<h2><span class="chapter-number">1</span> Definition of Emergency Medicine</h2>

<div class="definition-box">
    <strong>Emergency Medicine:</strong> The medical specialty concerned with the care of illnesses or injuries requiring immediate medical attention. Emergency physicians, also known as emergency medicine doctors, specialize in providing care for unscheduled and undifferentiated patients of all ages.
</div>

<h3>Core Principles of Emergency Medicine</h3>

<div class="clinical-pearl">
    <strong>üß† Clinical Pearl:</strong> In emergency medicine, we often have to make critical decisions with incomplete information. The priority is always "First, do no harm" while stabilizing life-threatening conditions.
</div>

<h4>Key Characteristics:</h4>
<ul>
    <li><strong>Time-Critical Nature:</strong> Interventions must occur within specific time frames ("golden hour," "platinum 10 minutes")</li>
    <li><strong>Undifferentiated Patients:</strong> Patients present without prior diagnosis; rapid assessment is crucial</li>
    <li><strong>Resource-Limited Environment:</strong> Often working with incomplete information or limited resources</li>
    <li><strong>Multisystem Approach:</strong> Must consider multiple organ systems simultaneously</li>
    <li><strong>Continuum of Care:</strong> Focus on stabilization before transfer to definitive care</li>
    <li><strong>Team-Based Care:</strong> Collaboration with nurses, paramedics, and specialists</li>
    <li><strong>High-Stakes Decision Making:</strong> Decisions can mean life or death</li>
</ul>

<h4>The Emergency Medicine Mindset:</h4>
<ol>
    <li><strong>ABCDE Approach:</strong> Airway, Breathing, Circulation, Disability, Exposure</li>
    <li><strong>Treat First What Kills First:</strong> Prioritize immediate life threats</li>
    <li><strong>Rule Out Worst-Case Scenario:</strong> Consider the most dangerous possibilities first</li>
    <li><strong>Reassess Continuously:</strong> Patients can deteriorate rapidly</li>
</ol>

<!-- CHAPTER 2 -->
<div class="page-break"></div>
<h2><span class="chapter-number">2</span> Difference Between Key Pharmacological Terms</h2>

<div class="warning-box">
    <strong>‚ö†Ô∏è Critical Understanding:</strong> These distinctions are not just academic‚Äîthey have direct implications for patient safety, documentation, and legal responsibility.
</div>

<h3>2.1 Indication vs Contraindication</h3>

<table class="comparison-table">
    <thead>
        <tr>
            <th style="width: 35%;">Term</th>
            <th>Definition</th>
            <th>Example in Emergency Medicine</th>
            <th>Clinical Significance</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td><strong>Indication</strong></td>
            <td>A valid reason to use a particular test, medication, procedure, or surgery</td>
            <td><em>Adrenaline:</em> Cardiac arrest, anaphylaxis, severe asthma</td>
            <td>Justifies the use of a treatment; evidence-based application</td>
        </tr>
        <tr>
            <td><strong>Contraindication</strong></td>
            <td>A specific situation in which a drug, procedure, or surgery should NOT be used</td>
            <td><em>Streptokinase:</em> Active internal bleeding, recent stroke</td>
            <td>Prevents harm; using despite contraindication may be malpractice</td>
        </tr>
        <tr>
            <td><strong>Absolute Contraindication</strong></td>
            <td>A situation that makes a treatment completely inadvisable</td>
            <td><em>ACE inhibitors:</em> Pregnancy (especially 2nd & 3rd trimester)</td>
            <td>Never use in this situation</td>
        </tr>
        <tr>
            <td><strong>Relative Contraindication</strong></td>
            <td>A situation where caution is advised but treatment may proceed if benefits outweigh risks</td>
            <td><em>Contrast dye:</em> Mild allergy with pretreatment possible</td>
            <td>Requires careful risk-benefit analysis</td>
        </tr>
    </tbody>
</table>

<h3>2.2 Side Effect vs Adverse Effect vs ADR</h3>

<div class="clinical-pearl">
    <strong>üß† Clinical Pearl:</strong> All drugs have side effects. The key is distinguishing between expected, manageable side effects and dangerous adverse reactions.
</div>

<table class="comparison-table">
    <thead>
        <tr>
            <th style="width: 30%;">Term</th>
            <th>Definition</th>
            <th>Example</th>
            <th>Severity & Management</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td><strong>Side Effect</strong></td>
            <td>A secondary, typically undesirable effect of a drug or medical treatment</td>
            <td>Nausea from morphine, dry mouth from atropine</td>
            <td>Usually predictable, manageable, often dose-dependent</td>
        </tr>
        <tr>
            <td><strong>Adverse Effect</strong></td>
            <td>A harmful or abnormal result caused by medication</td>
            <td>Respiratory depression from opioids, arrhythmia from adrenaline</td>
            <td>More serious, may require intervention or discontinuation</td>
        </tr>
        <tr>
            <td><strong>Adverse Drug Reaction (ADR)</strong></td>
            <td>Any noxious, unintended, and undesired effect of a drug at normal doses</td>
            <td>Anaphylaxis to penicillin, Stevens-Johnson syndrome</td>
            <td>Serious, potentially life-threatening, must be reported</td>
        </tr>
        <tr>
            <td><strong>Type A ADR</strong><br>(Augmented)</td>
            <td>Dose-dependent, predictable from drug's pharmacology</td>
            <td>Bradycardia from beta-blocker overdose</td>
            <td>Common (80% of ADRs), predictable, dose-related</td>
        </tr>
        <tr>
            <td><strong>Type B ADR</strong><br>(Bizarre)</td>
            <td>Not dose-dependent, unpredictable, often immunological</td>
            <td>Anaphylaxis, drug-induced lupus</td>
            <td>Uncommon, unpredictable, often severe</td>
        </tr>
    </tbody>
</table>

<!-- CHAPTER 3 -->
<div class="page-break"></div>
<h2><span class="chapter-number">3</span> Routes of Injectable Administration</h2>

<h3>3.1 Overview of Injectable Routes</h3>

<div class="warning-box">
    <strong>‚ö†Ô∏è Critical Skill:</strong> Choosing the correct route is as important as choosing the correct drug. The wrong route can render treatment ineffective or cause harm.
</div>

<table class="comparison-table">
    <thead>
        <tr>
            <th style="width: 15%;">Route</th>
            <th style="width: 20%;">Abbreviation</th>
            <th>Description</th>
            <th style="width: 25%;">Typical Onset of Action</th>
            <th style="width: 20%;">Common Emergency Uses</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td><strong>IV Bolus</strong></td>
            <td>IV push, IV stat</td>
            <td>Direct injection into vein over seconds to minutes</td>
            <td>15-30 seconds</td>
            <td>Cardiac arrest drugs, rapid sequence intubation, status epilepticus</td>
        </tr>
        <tr>
            <td><strong>IV Infusion</strong></td>
            <td>IV drip, IV infusion</td>
            <td>Continuous administration via infusion pump or gravity</td>
            <td>Minutes (depends on rate)</td>
            <td>Vasopressors, antiarrhythmics, maintenance fluids</td>
        </tr>
        <tr>
            <td><strong>Intramuscular</strong></td>
            <td>IM</td>
            <td>Injection into muscle (deltoid, vastus lateralis, ventrogluteal)</td>
            <td>5-15 minutes</td>
            <td>Anaphylaxis (adrenaline), sedation, antipsychotics, vaccines</td>
        </tr>
        <tr>
            <td><strong>Subcutaneous</strong></td>
            <td>SC, SubQ</td>
            <td>Injection into fatty tissue beneath skin</td>
            <td>15-30 minutes</td>
            <td>Insulin, heparin, some vaccines</td>
        </tr>
        <tr>
            <td><strong>Intraosseous</strong></td>
            <td>IO</td>
            <td>Injection into bone marrow cavity</td>
            <td>Similar to IV</td>
            <td>Emergency access when IV not possible (all emergency drugs)</td>
        </tr>
    </tbody>
</table>

<h3>3.2 Detailed Route Characteristics</h3>

<h4>IV Bolus (Intravenous Push)</h4>
<ul>
    <li><strong>Advantages:</strong> Immediate effect, complete bioavailability, precise control</li>
    <li><strong>Disadvantages:</strong> Risk of extravasation, phlebitis, rapid adverse effects</li>
    <li><strong>Maximum Rate Guidelines:</strong>
        <ul class="sub-list">
            <li>Potassium chloride: NEVER IV push (cardiac arrest risk)</li>
            <li>Magnesium sulfate: 1-2 minutes for loading dose</li>
            <li>Lidocaine: 1-3 minutes (50 mg/min maximum)</li>
        </ul>
    </li>
</ul>

<h4>Intraosseous (IO) Access</h4>
<div class="clinical-pearl">
    <strong>üß† Clinical Pearl:</strong> IO is NOT a last resort‚Äîit's an alternative first-line access in critical situations. All resuscitation drugs given IV can be given IO at the same dose.
</div>
<ul>
    <li><strong>Primary Sites:</strong> Proximal tibia, distal tibia, proximal humerus, sternum</li>
    <li><strong>Flow Rates:</strong> 2-5 L/hr possible with pressure bag</li>
    <li><strong>Duration:</strong> Remove within 24 hours (risk of osteomyelitis)</li>
    <li><strong>Special Considerations:</strong> Painful (consider lidocaine), requires pressure for infusion</li>
</ul>

<div class="figure">
    <div style="background-color: #ecf0f1; padding: 20px; border-radius: 5px; text-align: left;">
        <strong>üìä Injection Site Selection Guide:</strong>
        <ul>
            <li><strong>Deltoid (IM):</strong> Max 2 mL volume</li>
            <li><strong>Vastus Lateralis (IM):</strong> Max 5 mL (adults), 2-3 mL (children)</li>
            <li><strong>Ventrogluteal (IM):</strong> Safest site, max 4 mL</li>
            <li><strong>Dorsogluteal (IM):</strong> AVOID (risk of sciatic nerve injury)</li>
            <li><strong>Abdomen (SC):</strong> Rotate sites, avoid 2-inch circle around navel</li>
        </ul>
    </div>
    <div class="caption">Figure 3.1: Recommended injection sites and maximum volumes</div>
</div>

<!-- CHAPTER 4 -->
<div class="page-break"></div>
<h2><span class="chapter-number">4</span> Drug Preparation Basics</h2>

<h3>4.1 The Three C's of Drug Preparation</h3>

<div class="warning-box">
    <strong>‚ö†Ô∏è Medication Error Alert:</strong> Up to 50% of medication errors occur during the preparation and administration phase. Always double-check calculations!
</div>

<table class="comparison-table">
    <thead>
        <tr>
            <th style="width: 30%;">Concept</th>
            <th>Definition</th>
            <th>Calculation Formula</th>
            <th>Example</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td><strong>Dilution</strong></td>
            <td>Adding a solvent (usually normal saline or sterile water) to a concentrated drug</td>
            <td>Volume needed = (Desired concentration √ó Desired volume) / Stock concentration</td>
            <td>Make 1 mg/mL adrenaline from 1:1000 (1 mg/mL): No dilution needed</td>
        </tr>
        <tr>
            <td><strong>Concentration</strong></td>
            <td>Amount of drug per unit volume</td>
            <td>Concentration = Amount of drug (mg) / Volume (mL)</td>
            <td>1:1000 adrenaline = 1 mg/mL</td>
        </tr>
        <tr>
            <td><strong>Compatibility</strong></td>
            <td>Ability of drugs to be mixed without physical or chemical interaction</td>
            <td>N/A - Refer to compatibility charts</td>
            <td>Adrenaline compatible with most IV fluids; incompatible with sodium bicarbonate</td>
        </tr>
    </tbody>
</table>

<h3>4.2 Common Emergency Drug Concentrations</h3>

<div class="clinical-pearl">
    <strong>üß† Clinical Pearl:</strong> Memorize these common concentrations‚Äîthey're tested frequently and used daily in emergency practice.
</div>

<ul>
    <li><strong>Adrenaline (Epinephrine):</strong>
        <ul class="sub-list">
            <li>1:1000 = 1 mg/mL (IM for anaphylaxis)</li>
            <li>1:10,000 = 0.1 mg/mL (IV for cardiac arrest)</li>
        </ul>
    </li>
    <li><strong>Atropine:</strong> 0.1 mg/mL, 0.5 mg/mL, 1 mg/mL</li>
    <li><strong>Lidocaine:</strong> 1% = 10 mg/mL, 2% = 20 mg/mL</li>
    <li><strong>Morphine:</strong> 10 mg/mL, 15 mg/mL</li>
    <li><strong>Midazolam:</strong> 1 mg/mL, 5 mg/mL</li>
    <li><strong>Diazepam:</strong> 5 mg/mL</li>
</ul>

<h3>4.3 Y-Site Compatibility Rules</h3>

<div class="warning-box">
    <strong>‚ö†Ô∏è Critical Rule:</strong> When in doubt about compatibility, use separate IV lines. Precipitation or inactivation can occur instantly.
</div>

<h4>Common Incompatibilities (NEVER MIX):</h4>
<ul>
    <li><strong>Adrenaline + Sodium bicarbonate:</strong> Forms precipitate, inactivates adrenaline</li>
    <li><strong>Phenytoin + Most solutions:</strong> Precipitates in dextrose or other drugs</li>
    <li><strong>Amiodarone + Sodium bicarbonate:</strong> Incompatible</li>
    <li><strong>Insulin + Most emergency drugs:</strong> Adsorbs to plastic, inconsistent delivery</li>
</ul>

<h4>Always Compatible (Safe to Mix):</h4>
<ul>
    <li>Normal Saline (0.9% NaCl) with most emergency drugs</li>
    <li>5% Dextrose (D5W) with most drugs (except phenytoin)</li>
    <li>Lactated Ringer's with most drugs (caution with amphotericin, some antibiotics)</li>
</ul>

<!-- CHAPTER 5 -->
<div class="page-break"></div>
<h2><span class="chapter-number">5</span> Emergency Drug Safety</h2>

<h3>5.1 High-Alert Medications</h3>

<div class="definition-box">
    <strong>High-Alert Medications:</strong> Drugs that bear a heightened risk of causing significant patient harm when used in error. Although mistakes may or may not be more common with these drugs, the consequences of an error are clearly more devastating.
</div>

<h4>Institute for Safe Medication Practices (ISMP) List (Emergency Focus):</h4>

<div class="drug-list">
    <ul>
        <li><strong>Adrenergic agonists</strong> (IV): adrenaline, noradrenaline</li>
        <li><strong>Adrenergic antagonists</strong> (IV): propranolol, metoprolol</li>
        <li><strong>Anesthetic agents</strong> (IV): propofol, ketamine</li>
        <li><strong>Antiarrhythmics</strong> (IV): amiodarone, lidocaine</li>
        <li><strong>Anticoagulants</strong> (IV): heparin, warfarin</li>
        <li><strong>Cardioplegic solutions</strong></li>
        <li><strong>Chemotherapeutic agents</strong></li>
        <li><strong>Dextrose</strong> (hypertonic, ‚â•20%)</li>
        <li><strong>Dialysis fluids</strong> (peritoneal and hemodialysis)</li>
        <li><strong>Epidural/intrathecal medications</strong></li>
        <li><strong>Inotropic agents</strong> (IV): dopamine, dobutamine</li>
        <li><strong>Insulin</strong> (all forms)</li>
        <li><strong>Lipid emulsion</strong> (IV)</li>
        <li><strong>Magnesium sulfate injection</strong></li>
        <li><strong>Moderate sedation agents</strong> (IV): midazolam</li>
        <li><strong>Moderate/opioid agonists</strong> (IV): fentanyl, morphine</li>
        <li><strong>Neuromuscular blocking agents</strong>: succinylcholine, rocuronium</li>
        <li><strong>Opium tincture</strong></li>
        <li><strong>Potassium chloride for injection</strong></li>
        <li><strong>Potassium phosphate injection</strong></li>
        <li><strong>Sodium chloride injection</strong> (hypertonic, >0.9%)</li>
        <li><strong>Sterile water for injection</strong> (in containers of >100 mL)</li>
        <li><strong>Thrombolytics/fibrinolytics</strong>: alteplase, tenecteplase</li>
        <li><strong>Total parenteral nutrition solutions</strong></li>
    </ul>
</div>

<h3>5.2 Look-Alike/Sound-Alike (LASA) Drugs</h3>

<div class="clinical-pearl">
    <strong>üß† Clinical Pearl:</strong> Always read labels THREE times: when taking from storage, when preparing, and when administering. Never rely on memory or similar-sounding names.
</div>

<table class="comparison-table">
    <thead>
        <tr>
            <th style="width: 25%;">Drug Pair</th>
            <th>Differences</th>
            <th>Potential Error</th>
            <th>Safety Strategy</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td><strong>Dopamine vs Dobutamine</strong></td>
            <td>Dopamine: renal dose 1-3 mcg/kg/min, cardiac 5-10 mcg/kg/min<br>Dobutamine: 2-20 mcg/kg/min</td>
            <td>Wrong choice for shock type</td>
            <td>Separate storage, label clearly</td>
        </tr>
        <tr>
            <td><strong>Hydralazine vs Hydroxyzine</strong></td>
            <td>Hydralazine: antihypertensive<br>Hydroxyzine: antihistamine</td>
            <td>Wrong drug for hypertension vs anxiety</td>
            <td>Tall man lettering: hydrALAzine vs hydrOXYzine</td>
        </tr>
        <tr>
            <td><strong>Insulin Regular vs NPH</strong></td>
            <td>Regular: clear, rapid-acting<br>NPH: cloudy, intermediate-acting</td>
            <td>Wrong insulin type causing hypo/hyperglycemia</td>
            <td>Store separately, never mix up</td>
        </tr>
        <tr>
            <td><strong>Lorazepam vs Alprazolam</strong></td>
            <td>Lorazepam: longer half-life, status epilepticus<br>Alprazolam: shorter half-life, anxiety</td>
            <td>Wrong benzodiazepine choice</td>
            <td>Clear labeling, different storage</td>
        </tr>
        <tr>
            <td><strong>Morphine vs Hydromorphone</strong></td>
            <td>Morphine: 10 mg IV = 1.5 mg hydromorphone IV</td>
            <td>10x overdose if substituted mg for mg</td>
            <td>Double-check conversion, separate storage</td>
        </tr>
    </tbody>
</table>

<h4>Tall Man Lettering (Official ISMP List):</h4>
<ul>
    <li>chlorproMAZINE vs chlorproPAMIDE</li>
    <li>clomiPHENE vs clomiPRAMINE</li>
    <li>dimenhyDRINATE vs diphenhydrAMINE</li>
    <li>DOBUTamine vs DOPamine</li>
    <li>GLIPIZIDE vs GLYBURIDE</li>
    <li>hydrALAzine vs hydrOXYzine</li>
    <li>prednisONE vs prednisOLONE</li>
    <li>vinBLAStine vs vinCRIStine</li>
</ul>

<!-- CHAPTER 6 -->
<div class="page-break"></div>
<h2><span class="chapter-number">6</span> Pediatric vs Adult Dosing Principles</h2>

<h3>6.1 Fundamental Differences</h3>

<div class="warning-box">
    <strong>‚ö†Ô∏è Critical Warning:</strong> Children are NOT small adults. Their pharmacokinetics differ significantly. Never simply "divide the adult dose."
</div>

<table class="comparison-table">
    <thead>
        <tr>
            <th style="width: 20%;">Parameter</th>
            <th>Pediatric Considerations</th>
            <th>Adult Considerations</th>
            <th>Clinical Implications</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td><strong>Body Composition</strong></td>
            <td>Higher water content (80% vs 60%), lower fat</td>
            <td>Lower water content, variable fat</td>
            <td>Water-soluble drugs: higher mg/kg dose needed</td>
        </tr>
        <tr>
            <td><strong>Protein Binding</strong></td>
            <td>Lower albumin, less protein binding</td>
            <td>Normal protein binding</td>
            <td>Higher free drug levels in children</td>
        </tr>
        <tr>
            <td><strong>Hepatic Metabolism</strong></td>
            <td>Immature enzyme systems (especially neonates)</td>
            <td>Mature enzyme systems</td>
            <td>Longer half-lives in neonates for some drugs</td>
        </tr>
        <tr>
            <td><strong>Renal Excretion</strong></td>
            <td>Lower GFR (especially <6 months)</td>
            <td>Normal or reduced GFR</td>
            <td>Renally excreted drugs: reduce dose in infants</td>
        </tr>
        <tr>
            <td><strong>Blood-Brain Barrier</strong></td>
            <td>More permeable in infants</td>
            <td>Fully developed</td>
            <td>Increased CNS effects in children</td>
        </tr>
    </tbody>
</table>

<h3>6.2 Dosing Calculations Methods</h3>

<div class="clinical-pearl">
    <strong>üß† Clinical Pearl:</strong> Always calculate pediatric doses using weight (mg/kg). For emergencies, use length-based systems (Broselow tape) when weight is unknown.
</div>

<h4>Common Pediatric Dosing Methods:</h4>
<ol>
    <li><strong>Weight-Based (mg/kg):</strong> Most common method
        <ul class="sub-list">
            <li>Formula: Dose = Weight (kg) √ó Dose per kg</li>
            <li>Example: Paracetamol 15 mg/kg for 20 kg child = 300 mg</li>
        </ul>
    </li>
    <li><strong>Body Surface Area (mg/m¬≤):</strong> More accurate for chemotherapy
        <ul class="sub-list">
            <li>Mosteller formula: BSA (m¬≤) = ‚àö[height (cm) √ó weight (kg) / 3600]</li>
        </ul>
    </li>
    <li><strong>Age-Based Rules:</strong> Quick estimation
        <ul class="sub-list">
            <li>Clark's rule: Child dose = (Weight in lbs/150) √ó Adult dose</li>
            <li>Young's rule: Child dose = [Age/(Age + 12)] √ó Adult dose</li>
        </ul>
    </li>
</ol>

<h3>6.3 Broselow Tape / Length-Based Systems</h3>

<div class="figure">
    <div style="background-color: #ecf0f1; padding: 20px; border-radius: 5px; text-align: left;">
        <strong>üìè Broselow Color Zones (Simplified):</strong>
        <ul>
            <li><strong>Gray:</strong> 3-5 kg, 46-55 cm (Neonate)</li>
            <li><strong>Pink:</strong> 6-7 kg, 56-65 cm (3-6 months)</li>
            <li><strong>Red:</strong> 8-9 kg, 66-75 cm (6-11 months)</li>
            <li><strong>Purple:</strong> 10-11 kg, 76-85 cm (1 year)</li>
            <li><strong>Yellow:</strong> 12-14 kg, 86-95 cm (1-2 years)</li>
            <li><strong>White:</strong> 15-18 kg, 96-105 cm (2-4 years)</li>
            <li><strong>Blue:</strong> 19-23 kg, 106-115 cm (4-6 years)</li>
            <li><strong>Orange:</strong> 24-29 kg, 116-125 cm (6-8 years)</li>
            <li><strong>Green:</strong> 30-36 kg, 126-135 cm (8-10 years)</li>
        </ul>
    </div>
    <div class="caption">Figure 6.1: Broselow tape color zones with approximate ages and weights</div>
</div>

<h4>Broselow Advantages:</h4>
<ul>
    <li>Quick determination of weight when unknown</li>
    <li>Pre-calculated drug doses and equipment sizes</li>
    <li>Reduces calculation errors in emergencies</li>
    <li>Standardized across emergency departments</li>
</ul>

<!-- CHAPTER 7 -->
<div class="page-break"></div>
<h2><span class="chapter-number">7</span> Renal & Hepatic Dose Adjustment (Basic)</h2>

<h3>7.1 Renal Dose Adjustment</h3>

<div class="definition-box">
    <strong>Creatinine Clearance (CrCl):</strong> The volume of blood plasma cleared of creatinine per unit time. It's a useful measure for approximating the glomerular filtration rate (GFR).
</div>

<h4>Cockcroft-Gault Formula (Most Common):</h4>

<div style="background-color: #f8f9fa; padding: 15px; border-radius: 5px; margin: 15px 0; border-left: 4px solid #3498db;">
    <strong>CrCl (mL/min) = [(140 - Age) √ó Weight (kg)] / [72 √ó Serum Cr (mg/dL)]</strong><br>
    <em>For women: Multiply result by 0.85</em>
</div>

<h4>Renal Impairment Stages and Dosing:</h4>

<table class="comparison-table">
    <thead>
        <tr>
            <th style="width: 20%;">Stage</th>
            <th>GFR (mL/min)</th>
            <th>Serum Creatinine</th>
            <th>Dosing Adjustment</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td><strong>Normal</strong></td>
            <td>>90</td>
            <td><1.2 mg/dL</td>
            <td>No adjustment</td>
        </tr>
        <tr>
            <td><strong>Mild impairment</strong></td>
            <td>60-89</td>
            <td>1.2-1.9</td>
            <td>Usually no adjustment</td>
        </tr>
        <tr>
            <td><strong>Moderate impairment</strong></td>
            <td>30-59</td>
            <td>2.0-3.9</td>
            <td>Reduce dose by 25-50% or extend interval</td>
        </tr>
        <tr>
            <td><strong>Severe impairment</strong></td>
            <td>15-29</td>
            <td>4.0-6.0</td>
            <td>Reduce dose by 50-75%</td>
        </tr>
        <tr>
            <td><strong>Renal failure</strong></td>
            <td><15</td>
            <td>>6.0</td>
            <td>Avoid or use minimal doses with monitoring</td>
        </tr>
    </tbody>
</table>

<h4>Emergency Drugs Requiring Renal Adjustment:</h4>
<ul>
    <li><strong>Major adjustment needed:</strong>
        <ul class="sub-list">
            <li>Enoxaparin (LMWH)</li>
            <li>Gentamicin and other aminoglycosides</li>
            <li>Digoxin</li>
            <li>Lithium</li>
            <li>Most ACE inhibitors</li>
        </ul>
    </li>
    <li><strong>Minor or no adjustment:</strong>
        <ul class="sub-list">
            <li>Adrenaline (epinephrine)</li>
            <li>Atropine</li>
            <li>Diazepam (metabolized hepatically)</li>
            <li>Fentanyl</li>
        </ul>
    </li>
</ul>

<h3>7.2 Hepatic Dose Adjustment</h3>

<div class="clinical-pearl">
    <strong>üß† Clinical Pearl:</strong> Hepatic impairment is harder to quantify than renal impairment. Use Child-Pugh score as a guide, but clinical judgment is essential.
</div>

<h4>Child-Pugh Classification:</h4>

<table class="comparison-table">
    <thead>
        <tr>
            <th style="width: 15%;">Parameter</th>
            <th>1 point</th>
            <th>2 points</th>
            <th>3 points</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td><strong>Albumin (g/dL)</strong></td>
            <td>>3.5</td>
            <td>2.8-3.5</td>
            <td><2.8</td>
        </tr>
        <tr>
            <td><strong>Bilirubin (mg/dL)</strong></td>
            <td><2</td>
            <td>2-3</td>
            <td>>3</td>
        </tr>
        <tr>
            <td><strong>INR</strong></td>
            <td><1.7</td>
            <td>1.7-2.3</td>
            <td>>2.3</td>
        </tr>
        <tr>
            <td><strong>Ascites</strong></td>
            <td>None</td>
            <td>Mild</td>
            <td>Moderate-Severe</td>
        </tr>
        <tr>
            <td><strong>Encephalopathy</strong></td>
            <td>None</td>
            <td>Grade 1-2</td>
            <td>Grade 3-4</td>
        </tr>
    </tbody>
</table>

<h4>Child-Pugh Scores and Dosing:</h4>
<ul>
    <li><strong>Class A (5-6 points):</strong> Mild disease - Usually no dose adjustment</li>
    <li><strong>Class B (7-9 points):</strong> Moderate disease - Reduce dose by 25-50%</li>
    <li><strong>Class C (10-15 points):</strong> Severe disease - Avoid or use minimal doses</li>
</ul>

<h4>Emergency Drugs Requiring Hepatic Adjustment:</h4>
<ul>
    <li><strong>Major adjustment needed:</strong>
        <ul class="sub-list">
            <li>Morphine (increased sensitivity)</li>
            <li>Midazolam (prolonged sedation)</li>
            <li>Lidocaine (reduced clearance)</li>
            <li>Propranolol (first-pass metabolism reduced)</li>
        </ul>
    </li>
    <li><strong>Safe in hepatic impairment:</strong>
        <ul class="sub-list">
            <li>Noradrenaline (norepinephrine)</li>
            <li>Dobutamine</li>
            <li>Atropine</li>
            <li>Furosemide</li>
        </ul>
    </li>
</ul>

<!-- CHAPTER 8 -->
<div class="page-break"></div>
<h2><span class="chapter-number">8</span> Anaphylaxis & Drug Reaction Management</h2>

<h3>8.1 Anaphylaxis Recognition</h3>

<div class="definition-box">
    <strong>Anaphylaxis:</strong> A severe, life-threatening, generalized or systemic hypersensitivity reaction characterized by rapidly developing life-threatening airway, breathing, and/or circulation problems usually associated with skin and mucosal changes.
</div>

<h4>Diagnostic Criteria (ANY ONE of the following):</h4>
<ol>
    <li><strong>Acute onset</strong> of illness (minutes to hours) with involvement of skin, mucosal tissue, or both (e.g., hives, pruritus, flushing, swollen lips/tongue/uvula) AND AT LEAST ONE OF:
        <ul class="sub-list">
            <li>Respiratory compromise (dyspnea, wheeze, stridor, hypoxemia)</li>
            <li>Reduced BP or associated symptoms (collapse, syncope, incontinence)</li>
        </ul>
    </li>
    <li><strong>Two or more</strong> of the following that occur rapidly after exposure to a likely allergen:
        <ul class="sub-list">
            <li>Involvement of skin/mucosa</li>
            <li>Respiratory compromise</li>
            <li>Reduced BP or associated symptoms</li>
            <li>Persistent gastrointestinal symptoms (cramping, vomiting)</li>
        </ul>
    </li>
    <li><strong>Reduced BP</strong> after exposure to known allergen:
        <ul class="sub-list">
            <li>Infants and children: Low systolic BP or >30% decrease</li>
            <li>Adults: Systolic BP <90 mmHg or >30% decrease from baseline</li>
        </ul>
    </li>
</ol>

<h3>8.2 Anaphylaxis Management Protocol</h3>

<div class="warning-box">
    <strong>‚ö†Ô∏è Emergency Protocol:</strong> Adrenaline FIRST, adrenaline FAST, adrenaline INTRAMUSCULAR (anterolateral thigh). Do not delay for IV access or other medications.
</div>

<h4>Step-by-Step Management:</h4>
<ol>
    <li><strong>Immediate Actions:</strong>
        <ul>
            <li>Remove trigger if possible (stop IV medication)</li>
            <li>Call for help (crash team, senior help)</li>
            <li>Place patient in supine position (or left lateral if pregnant)</li>
            <li>High-flow oxygen (15 L/min via non-rebreather mask)</li>
        </ul>
    </li>
    <li><strong>Adrenaline (Epinephrine) Administration:</strong>
        <ul>
            <li><strong>Route:</strong> IM anterolateral thigh (vastus lateralis)</li>
            <li><strong>Dose:</strong> 0.01 mg/kg of 1:1000 (max 0.5 mg adults, 0.3 mg children)</li>
            <li><strong>Repeat:</strong> Every 5 minutes if no improvement</li>
            <li><strong>IV adrenaline:</strong> Only if refractory anaphylaxis or cardiac arrest</li>
        </ul>
    </li>
    <li><strong>Secondary Medications:</strong>
        <ul>
            <li><strong>Chlorphenamine (Antihistamine):</strong> 10 mg IM/IV (child: 0.2 mg/kg)</li>
            <li><strong>Hydrocortisone (Steroid):</strong> 200 mg IM/IV (child: 2-4 mg/kg)</li>
        </ul>
    </li>
    <li><strong>Fluid Resuscitation:</strong>
        <ul>
            <li>Normal saline 500-1000 mL bolus (child: 20 mL/kg)</li>
            <li>Repeat if hypotensive</li>
        </ul>
    </li>
    <li><strong>Refractory Cases:</strong>
        <ul>
            <li>Adrenaline infusion: 0.05-0.1 mcg/kg/min</li>
            <li>Glucagon: 1-2 mg IM/IV if on beta-blockers</li>
            <li>Consider salbutamol neb if bronchospasm prominent</li>
        </ul>
    </li>
</ol>

<h3>8.3 Drug Reaction Classification and Management</h3>

<table class="comparison-table">
    <thead>
        <tr>
            <th style="width: 20%;">Reaction Type</th>
            <th>Onset</th>
            <th>Key Features</th>
            <th>Management</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td><strong>Anaphylaxis</strong></td>
            <td>Minutes-hours</td>
            <td>Multi-system, hypotension, airway compromise</td>
            <td>Adrenaline IM, fluids, antihistamines, steroids</td>
        </tr>
        <tr>
            <td><strong>Simple Rash</strong></td>
            <td>Hours-days</td>
            <td>Maculopapular, itchy, no systemic symptoms</td>
            <td>Stop drug, antihistamines, observation</td>
        </tr>
        <tr>
            <td><strong>DRESS</strong><br>(Drug Rash with Eosinophilia and Systemic Symptoms)</td>
            <td>2-8 weeks</td>
            <td>Fever, rash, eosinophilia, organ involvement</td>
            <td>Stop drug, systemic steroids, specialist referral</td>
        </tr>
        <tr>
            <td><strong>SJS/TEN</strong><br>(Stevens-Johnson/Toxic Epidermal Necrolysis)</td>
            <td>1-3 weeks</td>
            <td>Mucosal erosions, skin detachment, Nikolsky sign</td>
            <td>ICU, stop drug, burn care, avoid steroids</td>
        </tr>
        <tr>
            <td><strong>Serum Sickness</strong></td>
            <td>1-3 weeks</td>
            <td>Fever, arthralgia, urticaria, lymphadenopathy</td>
            <td>Stop drug, NSAIDs, antihistamines, steroids if severe</td>
        </tr>
    </tbody>
</table>

<!-- DRUG TEMPLATE EXAMPLE -->
<div class="page-break"></div>
<div class="study-format">
    <h2><span class="emoji">üß†</span> HOW WE WILL STUDY EACH DRUG (FIXED TEMPLATE)</h2>
    <p><strong>For every drug, we will follow ONE SAME FORMAT:</strong></p>
    <ol>
        <li><strong>Drug class</strong></li>
        <li><strong>Mechanism of action</strong></li>
        <li><strong>Indications</strong></li>
        <li><strong>Contraindications</strong></li>
        <li><strong>Adult dose</strong></li>
        <li><strong>Pediatric dose</strong> (if applicable)</li>
        <li><strong>Route & preparation</strong></li>
        <li><strong>Side effects</strong></li>
        <li><strong>Adverse effects / ADR</strong></li>
        <li><strong>Drug interactions</strong></li>
        <li><strong>Emergency pearls</strong> (exam + real life)</li>
    </ol>
</div>

<h3>Example Drug Template Application:</h3>

<div class="drug-template">
    <h4>ADRENALINE (EPINEPHRINE)</h4>
    
    <div class="template-section">
        <span class="template-label">Drug class:</span> Alpha and beta adrenergic agonist
    </div>
    
    <div class="template-section">
        <span class="template-label">Mechanism of action:</span> 
        ‚Ä¢ Alpha-1: Vasoconstriction ‚Üí increased BP, reduced mucosal edema<br>
        ‚Ä¢ Beta-1: Increased heart rate, contractility, cardiac output<br>
        ‚Ä¢ Beta-2: Bronchodilation, vasodilation in skeletal muscle
    </div>
    
    <div class="template-section">
        <span class="template-label">Indications:</span>
        ‚Ä¢ Cardiac arrest (VF/pulseless VT, PEA, asystole)<br>
        ‚Ä¢ Anaphylaxis<br>
        ‚Ä¢ Severe asthma/bronchospasm unresponsive to bronchodilators<br>
        ‚Ä¢ Symptomatic bradycardia (if atropine fails)<br>
        ‚Ä¢ Severe hypotension/shock
    </div>
    
    <div class="template-section">
        <span class="template-label">Contraindications:</span>
        ‚Ä¢ None in cardiac arrest (absolute emergency)<br>
        ‚Ä¢ Relative: Hypertension, coronary artery disease, arrhythmias
    </div>
    
    <div class="template-section">
        <span class="template-label">Adult dose:</span>
        ‚Ä¢ Cardiac arrest: 1 mg IV/IO every 3-5 minutes (1:10,000)<br>
        ‚Ä¢ Anaphylaxis: 0.3-0.5 mg IM (1:1000)<br>
        ‚Ä¢ Infusion: 0.05-0.1 mcg/kg/min (titrate to effect)
    </div>
    
    <div class="template-section">
        <span class="template-label">Pediatric dose:</span>
        ‚Ä¢ Cardiac arrest: 0.01 mg/kg IV/IO (max 1 mg)<br>
        ‚Ä¢ Anaphylaxis: 0.01 mg/kg IM (1:1000) max 0.3 mg
    </div>
    
    <div class="template-section">
        <span class="template-label">Route & preparation:</span>
        ‚Ä¢ IV bolus: Use 1:10,000 (0.1 mg/mL)<br>
        ‚Ä¢ IM: Use 1:1000 (1 mg/mL) in anterolateral thigh<br>
        ‚Ä¢ Infusion: Mix 1 mg in 250 mL NS = 4 mcg/mL
    </div>
    
    <div class="template-section">
        <span class="template-label">Side effects:</span>
        ‚Ä¢ Anxiety, tremor, headache, pallor<br>
        ‚Ä¢ Tachycardia, palpitations
    </div>
    
    <div class="template-section">
        <span class="template-label">Adverse effects / ADR:</span>
        ‚Ä¢ Severe hypertension<br>
        ‚Ä¢ Ventricular arrhythmias<br>
        ‚Ä¢ Myocardial ischemia/infarction<br>
        ‚Ä¢ Cerebral hemorrhage<br>
        ‚Ä¢ Pulmonary edema
    </div>
    
    <div class="template-section">
        <span class="template-label">Drug interactions:</span>
        ‚Ä¢ Beta-blockers: May cause severe hypertension<br>
        ‚Ä¢ TCAs, MAOIs: Potentiate effects<br>
        ‚Ä¢ Halogenated anesthetics: Risk of arrhythmias
    </div>
    
    <div class="template-section">
        <span class="template-label">Emergency pearls:</span>
        ‚Ä¢ In anaphylaxis: IM FIRST, NOT IV (IV can cause fatal arrhythmias)<br>
        ‚Ä¢ Cardiac arrest: Give during CPR, NOT during pulse checks<br>
        ‚Ä¢ Infusions: ALWAYS via central line if possible (tissue necrosis risk)<br>
        ‚Ä¢ Never mix with sodium bicarbonate (inactivates adrenaline)
    </div>
</div>

<!-- APPENDIX -->
<div class="page-break"></div>
<h2>Appendix: Quick Reference Tables</h2>

<h3>Common Emergency Drug Conversions</h3>
<table class="comparison-table">
    <thead>
        <tr>
            <th>Drug</th>
            <th>Common Concentration</th>
            <th>Equivalents</th>
            <th>Notes</th>
        </tr>
    </thead>
    <tbody>
        <tr>
            <td>Adrenaline</td>
            <td>1 mg/mL (1:1000)<br>0.1 mg/mL (1:10,000)</td>
            <td>1 mg = 1 mL of 1:1000<br>1 mg = 10 mL of 1:10,000</td>
            <td>DO NOT CONFUSE concentrations</td>
        </tr>
        <tr>
            <td>Atropine</td>
            <td>0.1 mg/mL, 0.5 mg/mL, 1 mg/mL</td>
            <td>0.5 mg = 0.5 mL of 1 mg/mL<br>0.5 mg = 5 mL of 0.1 mg/mL</td>
            <td>Cardiac arrest: 3 mg total</td>
        </tr>
        <tr>
            <td>Lidocaine</td>
            <td>1% = 10 mg/mL<br>2% = 20 mg/mL</td>
            <td>100 mg = 10 mL of 1%<br>100 mg = 5 mL of 2%</td>
            <td>Max 3 mg/kg without epi</td>
        </tr>
        <tr>
            <td>Morphine</td>
            <td>10 mg/mL, 15 mg/mL</td>
            <td>10 mg = 1 mL of 10 mg/mL</td>
            <td>Reduce dose in elderly, renal/hepatic impairment</td>
        </tr>
        <tr>
            <td>Midazolam</td>
            <td>1 mg/mL, 5 mg/mL</td>
            <td>5 mg = 5 mL of 1 mg/mL<br>5 mg = 1 mL of 5 mg/mL</td>
            <td>Respiratory depression risk</td>
        </tr>
    </tbody>
</table>

<h3>Time-Sensitive Interventions ("Golden Hours")</h3>
<ul>
    <li><strong>Myocardial infarction:</strong> Door-to-balloon <90 minutes, thrombolysis <30 minutes</li>
    <li><strong>Stroke:</strong> Door-to-needle (tPA) <60 minutes, thrombectomy <6 hours</li>
    <li><strong>Trauma:</strong> "Golden hour" concept, "platinum 10 minutes"</li>
    <li><strong>Sepsis:</strong> Antibiotics within 1 hour, lactate within 3 hours</li>
    <li><strong>Anaphylaxis:</strong> Adrenaline within 5 minutes</li>
    <li><strong>Status epilepticus:</strong> Benzodiazepines within 5 minutes</li>
</ul>

<div class="footer-note">
    <strong>¬© Emergency Medicine Education Team | Confidential Educational Material</strong><br>
    This document is for educational purposes only. Always follow local protocols and guidelines.<br>
    Medications and doses may vary by institution. Verify all information before clinical application.<br>
    Version 1.0 | Last updated: [Current Date]
</div></body> </html>